United Therapeutics (UTHR) Tops Q1 EPS by 19c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
JMP Securities Downgrades SteadyMed (STDY) to Market Perform Following Acquisition
May 1, 2018 3:25 AM EDTJMP Securities downgraded SteadyMed (NASDAQ: STDY) from Market Outperform to Market Perform.
Analyst Donald Ellis steps to the sideline following the recent acquisition by United Therapeutics (NASDAQ: UTHR). The analyst is not expecting a competing offer to... More
Pre-Open Movers 04/30: (STDY) (ANDV) (FDC) Higher; (CTB) (S) (ARNC) Lower (more...)
April 30, 2018 9:27 AM EDTToday's Pre-Open Movers
SteadyMed Ltd. (NASDAQ: STDY) 81.1% HIGHER; United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million.
Pluristem Therapeutics Inc. (Nasdaq:... More
